BioMarin Pharma (BMRN) Misses Q1 EPS by 8c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $91.87 +2.66%
Revenue Growth %: +8.9%
Financial Fact:
Total operating expenses: 339.98M
Today's EPS Names:
SFST, VLTO, CLIR, More
Revenue Growth %: +8.9%
Financial Fact:
Total operating expenses: 339.98M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of ($0.26), $0.08 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $373.4 million versus the consensus estimate of $348.57 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
- Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q1 EPS by 11c; raises guidance
- General Motors (GM) CFO: Expect to return to profits in Q2 in China
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
